ATE516300T1 - Neuromedin-u-rezeptoragonisten und ihre verwendung - Google Patents
Neuromedin-u-rezeptoragonisten und ihre verwendungInfo
- Publication number
- ATE516300T1 ATE516300T1 AT07753276T AT07753276T ATE516300T1 AT E516300 T1 ATE516300 T1 AT E516300T1 AT 07753276 T AT07753276 T AT 07753276T AT 07753276 T AT07753276 T AT 07753276T AT E516300 T1 ATE516300 T1 AT E516300T1
- Authority
- AT
- Austria
- Prior art keywords
- neuromedin
- receptor agonists
- obesity
- diabetes
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/43—Sweetening agents, e.g. thaumatin, monellin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78393306P | 2006-03-20 | 2006-03-20 | |
PCT/US2007/006635 WO2007109135A2 (en) | 2006-03-20 | 2007-03-16 | Neuromedin u receptor agonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE516300T1 true ATE516300T1 (de) | 2011-07-15 |
Family
ID=38522976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07753276T ATE516300T1 (de) | 2006-03-20 | 2007-03-16 | Neuromedin-u-rezeptoragonisten und ihre verwendung |
Country Status (15)
Country | Link |
---|---|
US (2) | US20070244048A1 (de) |
EP (1) | EP1999143B1 (de) |
JP (1) | JP2009530379A (de) |
KR (1) | KR20090005329A (de) |
CN (1) | CN101443356A (de) |
AT (1) | ATE516300T1 (de) |
AU (1) | AU2007227510A1 (de) |
BR (1) | BRPI0708943A2 (de) |
CA (1) | CA2647027A1 (de) |
IL (1) | IL193996A0 (de) |
MX (1) | MX2008012055A (de) |
NO (1) | NO20084380L (de) |
RU (1) | RU2008141280A (de) |
WO (1) | WO2007109135A2 (de) |
ZA (1) | ZA200807789B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1577323B1 (de) | 2002-12-26 | 2013-07-10 | Takeda Pharmaceutical Company Limited | Metastinderivat und verwendung davon |
CA2571420A1 (en) | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
TWI404726B (zh) | 2006-10-25 | 2013-08-11 | Takeda Pharmaceutical | 腫瘤轉移抑制素衍生物及其用途 |
EP2120985B1 (de) | 2007-02-05 | 2012-06-27 | Amylin Pharmaceuticals, Inc. | FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen |
JP2010539056A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのcnp−22単独、またはフィサレミンとの組合せの使用 |
EP2206721A1 (de) * | 2007-10-05 | 2010-07-14 | Takeda Pharmaceutical Company Limited | Neuromedin-u-derivat |
US20090104210A1 (en) * | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
SI2314609T1 (sl) * | 2008-07-30 | 2017-05-31 | Takeda Pharmaceutical Company Limited | Derivat metastina in njegova uporaba |
WO2010053830A1 (en) * | 2008-11-05 | 2010-05-14 | Merck Sharp & Dohme Corp. | Mechanism of neuromedin u action and uses thereof |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
JP5669728B2 (ja) * | 2009-04-08 | 2015-02-12 | 武田薬品工業株式会社 | ニューロメジンu誘導体 |
WO2010138343A1 (en) * | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists |
WO2011005611A1 (en) * | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
CN102595897A (zh) | 2009-09-02 | 2012-07-18 | 默沙东公司 | 作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃 |
WO2011053821A1 (en) * | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
US20120219538A1 (en) * | 2009-11-02 | 2012-08-30 | Therapeomic Ag | Stabilized protein formulations and use thereof |
US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
JP2013209295A (ja) | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
EP2838906A4 (de) | 2012-04-16 | 2015-07-15 | Kaneq Pharma Inc | Fusionierte aromatische phosphonatderivate als vorläufer für ptp-1b-inhibitoren |
EP2842965A1 (de) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin-U-Analoga mit Serumalbumin zur Bindung von Aminosäurerückständen |
US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
CN110183514B (zh) * | 2016-04-21 | 2022-12-30 | 上海天慈生命科学发展有限公司 | 一类阿片和神经肽ff受体的多靶点肽类分子及其制备和应用 |
WO2018109540A1 (en) | 2016-12-13 | 2018-06-21 | Instituto De Medicina Molecular | Methods of treating diseases associated with ilc2 cells |
JP7201967B2 (ja) * | 2017-01-20 | 2023-01-11 | 学校法人東京薬科大学 | ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ |
WO2018135642A1 (ja) * | 2017-01-20 | 2018-07-26 | 学校法人東京薬科大学 | ペプチド、その薬学的に許容される塩、またはそれらのプロドラッグ、およびそれらの用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2392774A1 (en) * | 1999-11-29 | 2001-06-07 | Takeda Chemical Industries, Ltd. | Screening method |
-
2007
- 2007-03-16 AT AT07753276T patent/ATE516300T1/de not_active IP Right Cessation
- 2007-03-16 RU RU2008141280/04A patent/RU2008141280A/ru not_active Application Discontinuation
- 2007-03-16 AU AU2007227510A patent/AU2007227510A1/en not_active Abandoned
- 2007-03-16 EP EP07753276A patent/EP1999143B1/de not_active Not-in-force
- 2007-03-16 MX MX2008012055A patent/MX2008012055A/es unknown
- 2007-03-16 US US11/724,846 patent/US20070244048A1/en not_active Abandoned
- 2007-03-16 CA CA002647027A patent/CA2647027A1/en not_active Abandoned
- 2007-03-16 KR KR1020087025492A patent/KR20090005329A/ko not_active Application Discontinuation
- 2007-03-16 BR BRPI0708943-0A patent/BRPI0708943A2/pt not_active IP Right Cessation
- 2007-03-16 CN CNA2007800174124A patent/CN101443356A/zh active Pending
- 2007-03-16 WO PCT/US2007/006635 patent/WO2007109135A2/en active Application Filing
- 2007-03-16 JP JP2009501467A patent/JP2009530379A/ja not_active Withdrawn
-
2008
- 2008-09-09 IL IL193996A patent/IL193996A0/en unknown
- 2008-09-10 ZA ZA200807789A patent/ZA200807789B/xx unknown
- 2008-10-17 NO NO20084380A patent/NO20084380L/no not_active Application Discontinuation
-
2009
- 2009-11-20 US US12/623,085 patent/US20100075907A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2647027A1 (en) | 2007-09-27 |
BRPI0708943A2 (pt) | 2011-06-14 |
WO2007109135A2 (en) | 2007-09-27 |
AU2007227510A1 (en) | 2007-09-27 |
RU2008141280A (ru) | 2010-04-27 |
JP2009530379A (ja) | 2009-08-27 |
ZA200807789B (en) | 2009-12-30 |
CN101443356A (zh) | 2009-05-27 |
KR20090005329A (ko) | 2009-01-13 |
MX2008012055A (es) | 2008-10-02 |
WO2007109135A3 (en) | 2008-04-03 |
EP1999143A2 (de) | 2008-12-10 |
NO20084380L (no) | 2008-12-16 |
EP1999143B1 (de) | 2011-07-13 |
IL193996A0 (en) | 2011-08-01 |
US20100075907A1 (en) | 2010-03-25 |
US20070244048A1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE516300T1 (de) | Neuromedin-u-rezeptoragonisten und ihre verwendung | |
CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
AU2007221366A8 (en) | Oxyntomodulin derivatives | |
WO2008008286A3 (en) | Substituted pyrazoles as ghrelin receptor antagonists | |
EP1993560A4 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
DK1984345T3 (da) | Benzoxaziner og beslægtede nitrogenholdige heterobicykliske forbindelser, der kan anvendes som mineralcorticoidreceptormodulerende midler | |
HK1136943A1 (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
MX2009005935A (es) | Compuestos biciclicos y su uso como anti-diabeticos. | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
ATE542816T1 (de) | Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors | |
NO20080010L (no) | GPCR-agonister | |
NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
BRPI0915282A2 (pt) | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
ATE476418T1 (de) | Benzamidderivate und assoziierte verwendungen | |
MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
EP1841781A4 (de) | Verwendung von il-22 zur behandlung von stoffwechselstörungen | |
MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
ZA200904281B (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |